Calidi Biotherapeutics, Inc. CLDI 深 滬
已收盤 07-31 16:00:00 美东时间
1.64
+0.147
+9.86%
華盛通- 最 高1.93
- 今 開1.93
- 成交量 46.37万股
- 最 低 1.53
- 昨 收 1.4928
- 總市值 3167.11万
- 52周最高 6.0594
- 市盈率 靜 --
- 換手率 2.40%
- 52周最低 0.0927
- 委 比 0.00%
- 總股本 1931.16万
- 歷史最高 2886.00
- 量 比 0.04
- 振 幅 26.80%
- 歷史最低 0.0927
- 每 手 1
- 風險率 21.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Crown Holdings Inc (NYSE:CCK) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY26 adjusted EPS guidance above estimates. Crown Holdings reported quarterly earnings of $2.49 per share which beat the analyst ...
07-21 17:11
Calidi Biotherapeutics Receives Pre-IND Regulatory Feedback From FDA Providing Alignment, Clarity On IND-Enabling Preclinical Plans And Clinical Strategy For CLD-401 Prior To Advancing Drug Candidate Into Phase 1 Clinical Studies
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it has received pre-IND regulatory feedback from the U.S. Food and Drug Administration (FDA) providing alignment and clarity on...
06-16 20:03
Calidi Biotherapeutics shares are trading lower. The company reported Q1 financial results.
Calidi Biotherapeutics shares are trading lower. The company reported Q1 financ...
05-15 21:06
Calidi Biotherapeutics Q1 EPS $(0.43) Beats $(1.56) Estimate
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(1.56) by 72.44 percent. This is a 80.09 percent increase over losses of $(2.16) per share
05-15 04:58
Why Bed Bath & Beyond Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Shares of Bed Bath & Beyond (BBBY) rose 23.4% in pre-market trading after beating revenue estimates. KIDZ, CLDI, DRCT, PFSA, KFRC, MLEC, SANM, SEI, DT are also up while VISN, ERAS, AREB, and YAAS are down.
04-28 17:11
Calidi Showcases RedTail Platform Data Highlighting Dual T-Cell Activation Strategy For Solid Tumors At AACR 2026
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California on April 19, 2026.
04-20 20:06
Calidi Biotherapeutics To Present New Data On Its Approach Of Simultaneously Activating T-Cells At American Association Of Cancer Research Annual Meeting
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of
04-01 20:03
Calidi Biotherapeutics Partners With Avance Clinical On Initiating First-In-Human Clinical Trial For CLD-401 In Australia
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced a partnership with Avance Clinical, a full-service
03-24 20:03
Calidi Biotherapeutics Presents Manufacturing Process For CLD-401
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today presented on its proprietary manufacturing process
03-12 20:07
Calidi Biotherapeutics shares are trading lower after the company announced the pricing of its $5.2 million offering of 10.5 million shares.
Calidi Biotherapeutics shares are trading lower after the company announced the...
03-06 22:25
